PTEN Monoclonal Antibody (2F4C9), Invitrogen™

Description

• 32-5800 reacts specifically with the human PTEN protein
• Reactivity was confirmed with cell lines which contain endogenous PTEN (NIH3T3, K652, and DU145 prostate cancer line) as well as transfected cell lines (Rat1 and 293T cells)
• This antibody detects the ∽55 kDa PTEN protein and was successfully used in western blotting analysis of PTEN in breast cancer cell lines
• No cross-reactivity to any other proteins has been detected
• PTEN was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency
• The PTEN gene is a phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase
• It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases
• Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates
• PTEN negatively regulates intracellular levels of phosphatidylinositol-3, 4, 5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway
• PTEN plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation
• Also, PTEN may be a negative regulator of insulin signaling and glucose metabolism in adipose tissue
• The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form of PTEN induces less tumor suppressive ability.